Inhibrx Biosciences Announces Clinical Update for INBRX‑106 in First‑Line HNSCC

What Happened
Inhibrx Biosciences, Inc. (INBX) filed a Form 8‑K on September 8, 2026 under Regulation FD to announce clinical updates for its investigational candidate INBRX‑106 in first‑line head and neck squamous cell carcinoma (HNSCC). The company furnished a press release announcing these updates as Exhibit 99.1 to the 8‑K; a corporate presentation was also listed as Exhibit 99.2. The filing was signed by Kelly Deck, Chief Financial Officer, on September 8, 2026.

Key Details

• Filing date: September 8, 2026 (Form 8‑K items 7.01 Regulation FD disclosure and 8.01 Other Events).
• Subject: Clinical updates regarding INBRX‑106 in first‑line HNSCC (head and neck squamous cell carcinoma).
• Materials furnished: Press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2).
• No financial results, executive changes, mergers, or other material corporate actions were reported in this filing.

Why It Matters
Clinical updates for INBRX‑106 are material to investors because trial progress and data can affect the development timeline, regulatory prospects, and perceived value of the company’s pipeline. By using a Regulation FD disclosure and furnishing a press release, Inhibrx is publicly sharing information that could influence investor decisions and market perception. Investors should review the furnished press release and presentation (Exhibits 99.1/99.2) for the specific trial data and pacing, and monitor subsequent filings or conference materials for further details.